With thousands fewer drug reps on the street these days, and many doctors turning reps away, companies have had to turn to new ways of promoting their products. What's Eli Lilly's version? According to an interview with Alex Azar, president of the Indianapolis-based company's U.S. business, it's problem-solving.
Over the past decade patent expiries have forced many Big Pharma to close production plants that supported decades of growth. With the current and next generations of small molecules and biologics raising the bar for manufacturing complexity, Eli Lilly, Merck and their peers face a choice: build plants or outsource?
After a manufacturing issue spiked its pitch for FDA approval, a new diabetes drug from Eli Lilly and Boehringer Ingelheim has secured European clearance, lining up to compete in a crowded market.
Just weeks after a federal jury in Louisiana gut-punched Takeda and Eli Lilly with a $9 billion verdict over diabetes drug Actos, an Illinois jury promptly let the company off the hook.
Eli Lilly lost a patent fight with Actavis in English High Court, in a ruling that paves the way for copycat competition not only in that country, but several others in Europe.
Eli Lilly has hotly denied and intends to fight the findings of a court in Brazil that could cost it nearly half a billion dollars to cover medical costs for former employees.
Eli Lilly in 2003 sold an antibiotics manufacturing plant in Cosmopolis, Brazil, to Italy's ACS Dobfar. But the fact that it has been more than a decade since Eli Lilly owned the facility has not kept the company from being ordered to pay $450 million to cover medical costs of dozens of plant employees for health problems they said came from exposure to hazardous materials.
Eli Lilly says its experimental diabetes therapy basal insulin peglispro beat out Sanofi's blockbuster Lantus for reducing levels of HbA1c in a trio of late-stage trials. But at least one prominent analyst swiftly raised questions about potential safety issues for this Lantus rival, which hopes to bite off a big piece of the market as Sanofi settles in for a lengthy legal battle to protect one of its bestselling products.
We've got an app for that. So drugmakers say in press releases we receive daily. But recasting the pharma business into a digital image? That could take an intervention. By Apple. And that intervention is reportedly on its way.
Thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage. We thought we'd look into the products whose prices have increased the most since 2007, to see how and why their prices are leaping.